Hostname: page-component-cd9895bd7-dk4vv Total loading time: 0 Render date: 2024-12-22T15:49:33.276Z Has data issue: false hasContentIssue false
  • English
  • Français

The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur

Published online by Cambridge University Press:  15 May 2009

P.-P. Pastoret  and
B. Brochier
P.-P. Pastoret
Affiliation:
Department of Immunology-Vaccinology, Faculty of Veterinary Medicine, B43 bis, University of Liège, B4000 Liège, Belgium
B. Brochier
Affiliation:
Department of Immunology-Vaccinology, Faculty of Veterinary Medicine, B43 bis, University of Liège, B4000 Liège, Belgium
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

To improve both safety and stability of the oral vaccines used in the field to vaccinate foxes against rabies, a recombinant vaccinia virus, which expresses the immunizing G protein of rabies virus has been developed by inserting the cDNA which codes for the immunogenic glycoprotein of rabies virus into the thymidine kinase (TK) gene of the Copenhagen strain of vaccinia virus. The efficacy of this vaccine was tested by the oral route, primarily in foxes. The immunity conferred, a minimum of 12 months in cubs and 18 months in adult animals, corresponds to the duration of the protection required for vaccination of foxes in the field. Innocuity was tested in foxes, domestic animals, and in numerous European wild animal species that could compete with the red fox for the vaccine bait. No clinical signs or lesions were observed in any of the vaccinated animals during a minimum of 28 days post vaccination. Moreover, no transmission of immunizing doses of the recombinant occurred between foxes or other species tested. To study the stability of the vaccine strain, baits containing the vaccine were placed in the field. Despite considerable variations of environmental temperatures, the vaccine remained stable for at least one month. Because bait is taken within one month, it can be assumed that most animals taking the baits are effectively vaccinated. To test the field efficacy of the recombinant vaccine, large-scale campaigns of fox vaccination were set up in a 2200 km2 region of southern Belgium, were rabies was prevalent. A dramatic decrease in the incidence of rabies was noted after the campaigns. The recombinant is presently used to control wildlife rabies in the field both in several European countries and in the United States.

Type
Special Article
Information
Epidemiology & Infection , Volume 116 , Issue 3 , June 1996 , pp. 235 - 240
Copyright
Copyright © Cambridge University Press 1996

References

REFERENCES

1.Pasteur, L. Méthode pour preventir la rage après morsure. C R Acad Sci 1885; 101: 765–844.Google Scholar
2.Pastoret, PP, Boulanger, D, Brochier, B. Warning: regulations can damage your health. The case of rabies. Curr Opin Biotech 1994; 5: 239–43.CrossRefGoogle ScholarPubMed
3.Aubert, MFA, Masson, E, Artois, M et al. , Oral wildlife rabies vaccination field trials in Europe, with recent emphasis on France. Curr Top Microbiol Immunol 1994; 187: 219–41.Google ScholarPubMed
4.Brochier, B, Aubert, MFA, Pastoret, PP et al. , Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. Rev Sci Tech Off Int Ep. In press.Google Scholar
5.Plotkin, S, Fautini, B. eds. Vaccinia vaccination, vaccinology; Jenner, Pasteur and their successors. Paris: Elsevier, 1996.Google Scholar
6.Baer, GM. The natural history of rabies. 2nd edn.Boca Raton: CRC Press, 1991.Google Scholar
7.Pastoret, PP, Brochier, B, Languet, B et al. , Stability of recombinant vaccinia-rabies vaccine in veterinary use. Develop Biol Stand. In press.Google Scholar
8.Esposito, JJ, Knight, JC, Shaddock, JH et al. , Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology 1988; 165: 313–6.CrossRefGoogle ScholarPubMed
9.Kiény, MP, Lathe, R, Drillien, R et al. , Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984; 312: 163–6.CrossRefGoogle ScholarPubMed
10.Blancou, J, Kiény, MP, Lathe, R et al. , Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 1986; 322: 373–5.CrossRefGoogle ScholarPubMed
11.Pastoret, PP, Brochier, B, Blancou, J et al. , Development and deliberate release of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies. In: Smith, GL, Binns, M, eds. Recombinant poxviruses. Boca Raton: CRC Press, 1992: 163–206.Google Scholar
12.Brochier, B, Languet, B, Artois, M et al. , Efficacy of a baiting system for vaccinating foxes against rabies with vaccinia-rabies recombinant virus. Vet Rec 1990; 127: 165–7.Google ScholarPubMed
13.Pastoret, PP, Brochier, B, Boulanger, D. Target and non-target effects of a recombinant vaccinia-rabies virus developed for fox vaccination against rabies. Dev Biol Stand 1995; 84: 183–93.Google ScholarPubMed
14.Crouch, AC, Baxby, D, McCracken, CM et al. , Serological evidence for the reservoir hosts of cowpox virus in British wildlife. Epidemiol Infect 1995; 115: 185–91.CrossRefGoogle ScholarPubMed
15.Boulanger, D, Crouch, A, Brochier, B et al. , Serological survey for Orthopoxvirus infection of wild mammals in areas where a recombinant-rabies virus is used to vaccinate foxes against rabies. Vet Rec. In press.Google Scholar
16.Boulanger, D, Brochier, B, Crouch, A et al. , Comparison of the susceptibility of the red fox (Vulpes vulpes) to a vaccinia-rabies recombinant virus and to cowpox virus. Vaccine 1995; 13: 215–9.CrossRefGoogle ScholarPubMed
17.Brochier, B, Thomas, I, Bauduin, B et al. , Use of vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies. Vaccine 1990; 8: 101–4.CrossRefGoogle ScholarPubMed
18.Brochier, B, Blancou, J, Thomas, I et al. , Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species. J. Wildl Dis 1989; 25: 540–7.CrossRefGoogle ScholarPubMed
19.Pastoret, PP, Brochier, B. Le virus de la vaccine et ses proches parents. Ann Méd Vét 1990; 134: 207–20.Google Scholar
20.Pastoret, PP, Brochier, B, Languet, B et al. First field trial of fox vaccination against rabies with a vaccinia-rabies recombinant virus. Vet Rec 1988; 123: 481–3.CrossRefGoogle ScholarPubMed
21.Brochier, B, Boulanger, D, Costy, F et al. , Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature, 1991; 354: 520–2.CrossRefGoogle ScholarPubMed
22.Brochier, B, Boulanger, D, Costy, F et al. , Towards rabies elimination in Belgium by fox vaccination using a vaccinia-rabies glycoprotein recombinant virus. Vaccine 1994; 12: 1368–71.CrossRefGoogle ScholarPubMed
23.Brochier, B, Costy, F, DeConinck, V et al. , Epidemio-surveillance de la rage en Belgique: recrudescence en 1994. Ann Méd Vét 1995; 139: 263–73.Google Scholar